Travere Therapeutics, Inc. (TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGS - Slideshow

Travere Therapeutics secured FDA approval for FILSPARI, the first-ever treatment for focal segmental glomerulosclerosis (FSGS), a rare kidney disease with no prior approved therapies. The approval marks a milestone for FSGS patients, addressing a critical unmet medical need by targeting the disease’s underlying mechanisms rather than just symptoms. FILSPARI, an endothelin receptor antagonist, demonstrated significant proteinuria reduction in clinical trials, offering hope for slowing kidney function decline in FSGS patients. The company presented the approval in an April 2026 investor slide deck, highlighting its commercialization strategy and market potential for the newly approved drug. This breakthrough positions Travere as a leader in rare kidney disease treatments, potentially expanding its pipeline and investor confidence in specialized therapeutics.